Overcoming purification challenges in antibody therapeutics manufacturing with subdomain-specific affinity solutions
Immuno-Oncology Insights 2021; 2(5), 229–239
Published: 6 September 2021
Novel biotherapeutic antibody formats, such as bispecific monoclonal antibodies, Fab fragments, and Fc-fusion proteins have created new purification challenges in downstream processing. The use of bacterial surface proteins, such as Protein A, is not always the most efficient solution for the purification of these novel modalities. Affinity chromatography resins, specifically developed to bind antibody subdomain regions, can provide an alternative solution for a variety of antibody formats.